Research
-
Texas Immuno-Oncology Biorepository launches inaugural research study
March 1, 2023Much of our current information about how to treat cancer comes from clinical trials; however, there are limits to what we can learn from trials alone. Ronan Kelly, MD, chief of oncology at Baylor Scott & White Charles A. Sammons Cancer Center and the W.W. Caruth, Jr. Chair in Immunology at Baylor University Medical Center, […]Learn more Texas Immuno-Oncology Biorepository launches inaugural research study -
Physician profile: Byron Cryer, MD
December 1, 2022Byron Cryer, MD, chief of internal medicine at BUMC, shares his vision for patient care, physician training and the impact of philanthropy.Learn more Physician profile: Byron Cryer, MD -
Esophageal cancer breakthrough gets FDA approval
June 1, 2021Dr. Ronan Kelly authors study released in The New England Journal of Medicine on a global phase III clinical trial at 170 sites including Baylor University Medical Center in Dallas. The results of a study published in April in The New England Journal of Medicine (NEJM) found that the immunotherapy drug nivolumab (Opdivo®), if used […]Learn more Esophageal cancer breakthrough gets FDA approval -
The answer to successfully treating cancer lies within
March 1, 2021Baylor Scott & White Health fosters transformational immunology research that can lead to earlier diagnoses and novel immunotherapies through the new Texas Immuno-Oncology Biorepository (TIOB).Learn more The answer to successfully treating cancer lies within -
Drawing on the strength of the human body for innovative clinical trials
June 1, 2019Dr. Ronan Kelly, new chief of oncology at Baylor Scott & White Health – North Texas, is poised to help cancer patients benefit through greater access to novel research investigating next-generation immunotherapies.Learn more Drawing on the strength of the human body for innovative clinical trials




